Beam Therapeutics (BEAM) Invested Capital: 2019-2025
Historic Invested Capital for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $972.5 million.
- Beam Therapeutics' Invested Capital rose 21.61% to $972.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $972.5 million, marking a year-over-year increase of 21.61%. This contributed to the annual value of $741.9 million for FY2024, which is 25.22% down from last year.
- Beam Therapeutics' Invested Capital amounted to $972.5 million in Q3 2025, which was down 7.44% from $1.1 billion recorded in Q2 2025.
- Over the past 5 years, Beam Therapeutics' Invested Capital peaked at $1.1 billion during Q1 2025, and registered a low of $495.5 million during Q1 2021.
- Its 3-year average for Invested Capital is $896.6 million, with a median of $862.3 million in 2024.
- As far as peak fluctuations go, Beam Therapeutics' Invested Capital spiked by 317.14% in 2021, and later declined by 25.22% in 2024.
- Over the past 5 years, Beam Therapeutics' Invested Capital (Quarterly) stood at $868.9 million in 2021, then dropped by 13.48% to $751.8 million in 2022, then soared by 31.97% to $992.1 million in 2023, then dropped by 25.22% to $741.9 million in 2024, then grew by 21.61% to $972.5 million in 2025.
- Its last three reported values are $972.5 million in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.